Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease

The FDA on Friday approved Regeneron Pharmaceuticals’ Veopoz (pozelimab-bbfg), the first and only treatment indicated specifically for CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, according to the company.